Vaccination against the feline leukaemia virus: Outcome and response categories and long-term follow-up

Vaccine

Volumn 25, Issue 30 SPEC. ISS., 2007, Pages 5531-5539

  Hofmann Lehmann, Regina ^a   Cattori, Valentino ^a   Tandon, Ravi ^a   Boretti, Felicitas S ^a   Meli, Marina L ^a   Riond, Barbara ^a   Pepin, Andrea C ^a   Willi, Barbara ^a   Ossent, Pete ^a   Lutz, Hans ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Pathogenesis; Retrovirus; Vaccine

Indexed keywords

FELINE LEUKEMIA VIRUS VACCINE; VIRUS RNA;

ARTICLE; CAT DISEASE; FELINE LEUKEMIA VIRUS; FOLLOW UP; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNITY; LIFE EXPECTANCY; MOLECULAR BIOLOGY; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROVOCATION TEST; RNA ANALYSIS; TREATMENT OUTCOME; VIRUS CELL INTERACTION; VIRUS LOAD;

EID: 34447100460     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.12.022     Document Type: Article

References (49)

1. Jarrett W.F., Crawford E.M., Martin W.M., and Davie F. A virus-like particle associated with leukaemia (lymphosarcoma). Nature 202 (1964) 567-568
2. Hoover E.A., and Mullins J.I. Feline leukemia virus infection and diseases. J Am Vet Med Assoc 199 10 (1991) 1287-1297
3. Sarma P.S., and Log T. Subgroup classification of feline leukemia and sarcoma viruses by viral interference and neutralization tests. Virology 54 1 (1973) 160-169
4. Jarrett O., Laird H.M., and Hay D. Determinants of the host range of feline leukaemia viruses. J Gen Virol 20 2 (1973) 169-175
5. Jarrett O., Hardy Jr. W.D., Golder M.C., and Hay D. The frequency of occurrence of feline leukaemia virus subgroups in cats. Int J Cancer 21 3 (1978) 334-337
6. Neil J.C., Fulton R., Rigby M., and Stewart M. Feline leukaemia virus: generation of pathogenic and oncogenic variants. Curr Top Microbiol Immunol 171 (1991) 67-93
7. Roy-Burman P. Endogenous env elements: partners in generation of pathogenic feline leukemia viruses. Virus Genes 11 2-3 (1995) 147-161
8. Jarrett O. Pathogenicity of feline leukemia virus is commonly associated with variant viruses. Leukemia 6 Suppl. 3 (1992) 153S-154S
9. Overbaugh J., and Bangham C.R. Selection forces and constraints on retroviral sequence variation. Science 292 5519 (2001) 1106-1109
10. Overbaugh J., Donahue P.R., Quackenbush S.L., Hoover E.A., and Mullins J.I. Molecular cloning of a feline leukemia virus that induces fatal immunodeficiency disease in cats. Science 239 4842 (1988) 906-910
11. Rohn J.L., Moser M.S., Gwynn S.R., Baldwin D.N., and Overbaugh J. In vivo evolution of a novel, syncytium-inducing and cytopathic feline leukemia virus variant. J Virol 72 4 (1998) 2686-2696
12. Lutz H., Pedersen N., Higgins J., Hubscher U., Troy F.A., and Theilen G.H. Humoral immune reactivity to feline leukemia virus and associated antigens in cats naturally infected with feline leukemia virus. Cancer Res 40 10 (1980) 3642-3651
13. Lutz H., Pedersen N.C., and Theilen G.H. Course of feline leukemia virus infection and its detection by enzyme-linked immunosorbent assay and monoclonal antibodies. Am J Vet Res 44 11 (1983) 2054-2059
14. Hoover E.A., Olsen R.G., Hardy Jr. W.D., Schaller J.P., Mathes L.E., and Cockerell G.L. Biologic and immunologic response of cats to experimental infection with feline leukemia virus. Bibl Haematol 43 (1975) 180-183
15. Rojko J.L., and Kociba G.J. Pathogenesis of infection by the feline leukemia virus. J Am Vet Med Assoc 199 10 (1991) 1305-1310
16. Rojko J.L., Hoover E.A., Mathes L.E., Olsen R.G., and Schaller J.P. Pathogenesis of experimental feline leukemia virus infection. J Natl Cancer Inst 63 3 (1979) 759-768
17. Hardy Jr. W.D., Hess P.W., MacEwen E.G., McClelland A.J., Zuckerman E.E., Essex M., et al. Biology of feline leukemia virus in the natural environment. Cancer Res 36 2 pt 2 (1976) 582-588
18. Pedersen N.C., Theilen G., Keane M.A., Fairbanks L., Mason T., Orser B., et al. Studies of naturally transmitted feline leukemia virus infection. Am J Vet Res 38 10 (1977) 1523-1531
19. Flynn J.N., Dunham S.P., Watson V., and Jarrett O. Longitudinal analysis of feline leukemia virus-specific cytotoxic T lymphocytes: correlation with recovery from infection. J Virol 76 5 (2002) 2306-2315
20. Flynn J.N., Hanlon L., and Jarrett O. Feline leukaemia virus: protective immunity is mediated by virus-specific cytotoxic T lymphocytes. Immunology 101 1 (2000) 120-125
21. Madewell B.R., and Jarrett O. Recovery of feline leukaemia virus from non-viraemic cats. Vet Rec 112 15 (1983) 339-342
22. Rojko J.L., Hoover E.A., Quackenbush S.L., and Olsen R.G. Reactivation of latent feline leukaemia virus infection. Nature 298 5872 (1982) 385-388
23. Post J.E., and Warren L. Reactivation of latent feline leukemia virus. In: Hardy Jr. W.D., Essex M., and McClelland A.J. (Eds). Feline Leukemia virus (1980), Elsevier North Holland Inc., New York 151-155
24. Pacitti A.M., and Jarrett O. Duration of the latent state in feline leukaemia virus infections. Vet Rec 117 18 (1985) 472-474
25. Pedersen N.C., Meric S.M., Johnson L., Plucker S., and Theiler G.H. The clinical significance of latent feline leukemia virus infection in cats. Feline Pratice 14 (1984) 32-48
26. Hayes K.A., Rojko J.L., Tarr M.J., Polas P.J., Olsen R.G., and Mathes L.E. Atypical localised viral expression in a cat with feline leukaemia. Vet Rec 124 13 (1989) 344-346
27. Pacitti A.M., Jarrett O., and Hay D. Transmission of feline leukaemia virus in the milk of a non-viraemic cat. Vet Rec 118 14 (1986) 381-384
28. McClelland A.J., Hardy W.D., and Zuckerman E.E. Prognosis of healthy feline leukemia virus infected cats. In: Hardy W.D., Essex M., and McClelland A.J. (Eds). Development in Cancer Research (1980), Elsevier Scientific Publishing Company, Amsterdam, The Netherlands pp. 121-126
29. Sparkes A.H. Feline leukaemia virus and vaccination. J Feline Med Surg 5 2 (2003) 97-100
30. Sparkes A.H. Feline leukaemia virus: a review of immunity and vaccination. J Small Anim Pract 38 5 (1997) 187-194
31. Jarrett O., and Ganiere J.P. Comparative-studies of the efficacy of a recombinant feline leukemia virus vaccine. Vet Rec 138 1 (1996) 7-11
32. Hines D.L., Cutting J.A., Dietrich D.L., and Walsh J.A. Evaluation of efficacy and safety of an inactivated virus vaccine against feline leukemia virus infection. J Am Vet Med Assoc 199 10 (1991) 1428-1430
33. Hoover E.A., Perigo N.A., Quackenbush S.L., Mathiason-DuBard C.K., Overbaugh J.M., Kloetzer W.S., et al. Protection against feline leukemia virus infection by use of an inactivated virus vaccine. J Am Vet Med Assoc 199 10 (1991) 1392-1401
34. York S.M., and York C.J. Development of a whole killed feline leukemia virus vaccine. J Am Vet Med Assoc 199 10 (1991) 1419-1422
35. Tizard I., and Bass E.P. Evaluation of a killed, whole virion feline leukemia virus vaccine. J Am Vet Med Assoc 199 10 (1991) 1410-1413
36. Marciani D.J., Kensil C.R., Beltz G.A., Hung C.H., Cronier J., and Aubert A. Genetically-engineered subunit vaccine against feline leukaemia virus: protective immune response in cats. Vaccine 9 2 (1991) 89-96
37. Poulet H., Brunet S., Boularand C., Guiot A.L., Leroy V., Tartaglia J., et al. Efficacy of a canarypox virus-vectored vaccine against feline leukaemia. Vet Rec 153 5 (2003) 141-145
38. Hofmann-Lehmann R., Huder J.B., Gruber S., Boretti F., Sigrist B., and Lutz H. Feline leukaemia provirus load during the course of experimental infection and in naturally infected cats. J Gen Virol 82 Pt 7 (2001) 1589-1596
39. Torres A.N., Mathiason C.K., and Hoover E.A. Re-examination of feline leukemia virus: host relationships using real-time PCR. Virology 332 1 (2005) 272-283
40. Tandon R., Cattori V., Gomes-Keller M.A., Meli M.L., Golder M.C., Lutz H., et al. Quantitation of feline leukaemia virus viral and proviral loads by TaqMan real-time polymerase chain reaction. J Virol Methods 130 1-2 (2005) 124-132
41. Hofmann-Lehmann R., Tandon R., Boretti F.S., Meli M.L., Willi B., Cattori V., et al. Reassessment of feline leukaemia virus (FeLV) vaccines with novel sensitive molecular assays. Vaccine 24 8 (2006) 1087-1094
42. Lehmann R., Franchini M., Aubert A., Wolfensberger C., Cronier J., and Lutz H. Vaccination of cats experimentally infected with feline immunodeficiency virus, using a recombinant feline leukemia virus vaccine. J Am Vet Med Assoc 199 10 (1991) 1446-1452
43. Feline leukemia vaccine (inactivated). In: Monograph of the European Pharmacopoeia Commission; 2005. p. 761.
44. Lutz H., Pedersen N.C., Durbin R., and Theilen G.H. Monoclonal antibodies to three epitopic regions of feline leukemia virus p27 and their use in enzyme-linked immunosorbent assay of p27. J Immunol Methods 56 2 (1983) 209-220
45. Fischinger P.J., Blevins C.S., and Nomura S. Simple, quantitative assay for both xenotropic murine leukemia and ecotropic feline leukemia viruses. J Virol 14 (1974) 177-179
46. Pollock R.V., and Scarlett J.M. Randomized blind trial of a commercial FeLV vaccine. J Am Vet Med Assoc 196 4 (1990) 611-616
47. Cattori V., Tandon R., Pepin A., Lutz H., and Hofmann-Lehman R. Rapid detection of feline leukemia virus provirus integration into feline genomic DNA. Mol Cell Probes 20 3-4 (2006) 172-181
48. Hofmann-Lehmann R., Holznagel E., Aubert A., Ossent P., Reinacher M., and Lutz H. Recombinant FeLV vaccine: long-term protection and effect on course and outcome of FIV infection. Vet Immunol Immunopathol 46 1-2 (1995) 127-137
49. Hofmann-Lehmann R., Holznagel E., Ossent P., and Lutz H. Parameters of disease progression in long-term experimental feline retrovirus (feline immunodeficiency virus and feline leukemia virus) infections: Hematology, clinical chemistry and lymphocyte subsets. Clin Diagn Lab Immunol 4 1 (1997) 33-42